الرسائل الموجهة للمختصين الصحيين

مشاركة الصفحة

التاريخ
المنتج التاريخ معلومات السلامة المرفقات
Arava® -leflunomide

Risk of serious birth defects when administered during pregnancy<strong> </strong><strong>​</strong>

Methotrexate "Ebewe”

Recommendations to avoid potentially fatal dosing errors when using methotrexate “METHOTREXATE &amp;quot;EBEWE “ for autoimmune diseases

Roaccutne

Roaccutne (isotretinoin): An update on neuropsychiatric disorders.

soliqua (lixisenatide /insuline glargin) soliqua

(lixisenatide /insuline glargin):&nbsp; Important information on dosing.

Gilenya (fingolimod)

Gilenya (fingolimod)): New contraindication in pregnant women and in women of childbearing potential not using effective contraception.

Advaquin ( levofloxacin)

Advaquin ( levofloxacin): Risk of aortic aneurysm and dissection.

Darzalex (Daratumumab)

Darzalex (Daratumumab): New identified risk of hepatitis B reactivation.

Lemtrada® Alemtuzumab

Alemtuzumab (Lemtrada): New safety information.

Apixaban, Edoxaban, Dabigatran and Rivaroxaban

Direct Healthcare Professional Communication (DHPC) for the Direct Oral Anticoagulants (DOACs) Apixaban, Edoxaban, Dabigatran and Rivaroxaban.

blinatumomab

Blincyto (pembrolizumab):&nbsp;Risk of Medication Errors and Benzyl alcohol toxicity​.



هل استفدت من ما هو مقدم في هذه الصفحة؟
0 من الزوار ردوا بنعم من أصل0 مشاركة
السبب
السبب